PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : A61K 47/44, 47/14, A61P 31/22 — A1

(11) International Publication Number: WO 00/29027

(43) International Publication Date: 25 May 2000 (25.05.00)

(21) International Application Number: PCT/SE99/02043

(22) International Filing Date: 12 November 1999 (12.11.99)

(30) Priority Data:
9803929–0 18 November 1998 (18.11.98) SE

(71) Applicant *(for all designated States except US)*: MEDIVIR AB [SE/SE]; Lunastigen 7, S–141 44 Huddinge (SE).

(72) Inventor; and

(75) Inventor/Applicant *(for US only)*: LEKARE, Gunilla [SE/SE]; Solhagsgatan 3, S–784 50 Borlänge (SE).

(74) Agent: MORRISON, Iain; Medivir AB, Lunastigen 7, S–141 44 Huddinge (SE).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: ANTIVIRAL FORMULATIONS COMPRISING PROPYLENE GLYCOL AND AN ISOPROPYL ALKANOIC ACID ESTER

(57) Abstract

A topical composition comprising an antiinflammatory glucocorticoid and a nucleoside analogue antiviral agent in a pharmaceutical carrier characterized in that the carrier comprises about 15 to about 25 weight % propylene glycol and about 10 to about 25 weight percent isopropyl C_{12}–C_{22} alkanoic ester. The compositions have utility in the treatment or prophylaxis of herpesvirus infections and exhibit superior antiviral and therapeutic efficacy and an improved shelf life.